{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:44:35Z","timestamp":1790660675377,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Environ Sci Pollut Res"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11356-021-16427-4","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T15:02:36Z","timestamp":1632582156000},"page":"12336-12346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["In silico screening of potent inhibitors against COVID-19 key targets from a library of FDA-approved drugs"],"prefix":"10.1007","volume":"29","author":[{"given":"Mohammad A.","family":"Elmorsy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-6907","authenticated-orcid":false,"given":"Ahmed M.","family":"El-Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa H.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa","family":"Almeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Abdel-Daim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galal","family":"Yahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"key":"16427_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2174\/1871526520666200518073329","volume":"20","author":"C Annweiler","year":"2020","unstructured":"Annweiler C, Cao Z, Wu Y, Faucon E, Mouhat S, Kovacic H, Sabatier J-M (2020) Counter-regulatory \u2018Renin-Angiotensin\u2019 system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients. Infect Disord Drug Targets 20:407\u2013408. https:\/\/doi.org\/10.2174\/1871526520666200518073329","journal-title":"Infect Disord Drug Targets"},{"key":"16427_CR2","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res 178:104787","journal-title":"Antivir Res"},{"key":"16427_CR3","doi-asserted-by":"publisher","unstructured":"Carrouel F, Conte MP, Fisher J, Gon\u00e7alves LS, Dussart C, Llodra JC, Bourgeois D (2020) COVID-19: a recommendation to examine the effect of mouthrinses with \u03b2-cyclodextrin combined with citrox in preventing infection and progression. J Clin Med 9(4). https:\/\/doi.org\/10.3390\/jcm9041126","DOI":"10.3390\/jcm9041126"},{"issue":"10223","key":"16427_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","volume":"395","author":"JF-W Chan","year":"2020","unstructured":"Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J, Yip CC-Y, Poon RW-S, Tsoi H-W, Lo SK-F, Chan K-H, Poon VK-M, Chan W-M, Ip JD, Cai J-P, Cheng VC-C, Chen H et al (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet (London, England) 395(10223):514\u2013523. https:\/\/doi.org\/10.1016\/S0140-6736(20)30154-9","journal-title":"Lancet (London, England)"},{"issue":"10223","key":"16427_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J'a YT, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 395(10223):507\u2013513. https:\/\/doi.org\/10.1016\/S0140-6736(20)30211-7","journal-title":"Lancet (London, England)"},{"key":"16427_CR6","unstructured":"COVID live update: 153,582,535 cases and 3,218,212 deaths from the coronavirus - Worldometer (2021). https:\/\/www.worldometers.info\/coronavirus\/. Accessed 03 May 2021"},{"issue":"1","key":"16427_CR7","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1038\/s41467-020-18709-w","volume":"11","author":"A Douangamath","year":"2020","unstructured":"Douangamath A, Fearon D, Gehrtz P, Krojer T, Lukacik P, Owen CD, Resnick E, Strain-Damerell C, Aimon A, \u00c1br\u00e1nyi-Balogh P, Brand\u00e3o-Neto J, Carbery A, Davison G, Dias A, Downes TD, Dunnett L, Fairhead M, Firth JD, Jones SP et al (2020) Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun 11(1):5047. https:\/\/doi.org\/10.1038\/s41467-020-18709-w","journal-title":"Nat Commun"},{"issue":"Suppl 17","key":"16427_CR8","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1471-2105-13-S17-S5","volume":"13","author":"M Elhefnawi","year":"2012","unstructured":"Elhefnawi M, ElGamacy M, Fares M (2012) Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors. BMC Bioinformatics 13(Suppl 17):S5. https:\/\/doi.org\/10.1186\/1471-2105-13-S17-S5","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"16427_CR9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","volume":"28","author":"G Forni","year":"2021","unstructured":"Forni G, Mantovani A (2021) COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 28(2):626\u2013639. https:\/\/doi.org\/10.1038\/s41418-020-00720-9","journal-title":"Cell Death Differ"},{"key":"16427_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1053\/j.gastro.2020.05.053","volume":"159","author":"DE Freedberg","year":"2020","unstructured":"Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, Sobieszczyk ME, Markowitz DD, Gupta A, O\u2019Donnell MR, Li J, Tuveson DA, Jin Z, Turner WC, Landry DW (2020) Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology 159:1129\u20131131.e3. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.053","journal-title":"Gastroenterology"},{"key":"16427_CR11","doi-asserted-by":"publisher","unstructured":"Gautret P, Lagier J-C, Parola P, van Hoang T, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honor\u00e9 S, Colson P, Chabri\u00e8re E, La Scola B, Rolain J-M, Brouqui P, Raoult D (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents\u00a056(1):105949. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"issue":"3","key":"16427_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/vaccines9030243","volume":"9","author":"CE G\u00f3mez","year":"2021","unstructured":"G\u00f3mez CE, Perdiguero B, Esteban M (2021) Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2\/COVID-19. Vaccines 9(3):243. https:\/\/doi.org\/10.3390\/vaccines9030243","journal-title":"Vaccines"},{"key":"16427_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ddr.21656","volume":"81","author":"D Gurwitz","year":"2020","unstructured":"Gurwitz D (2020) Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 81:537\u2013540. https:\/\/doi.org\/10.1002\/ddr.21656","journal-title":"Drug Dev Res"},{"issue":"4","key":"16427_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/s41423-021-00648-1","volume":"18","author":"J Hu","year":"2021","unstructured":"Hu J, Peng P, Wang K, Fang L, Luo F-y, A-s J, B-z L, Tang N, A-l H (2021) Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cell Mol Immunol 18(4):1061\u20131063. https:\/\/doi.org\/10.1038\/s41423-021-00648-1","journal-title":"Cell Mol Immunol"},{"issue":"10223","key":"16427_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"},{"key":"16427_CR16","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/gutjnl-2020-321852","volume":"69","author":"T Janowitz","year":"2020","unstructured":"Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, Tuveson D (2020) Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut 69:1592\u20131597. https:\/\/doi.org\/10.1136\/gutjnl-2020-321852","journal-title":"Gut"},{"key":"16427_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","volume":"397","author":"MD Knoll","year":"2020","unstructured":"Knoll MD, Wonodi C (2020) Oxford\u2013AstraZeneca COVID-19 vaccine efficacy. Lancet 397:72\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(20)32623-4","journal-title":"Lancet"},{"issue":"10224","key":"16427_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England) 395(10224):565\u2013574. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8","journal-title":"Lancet (London, England)"},{"issue":"11","key":"16427_CR19","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1021\/acs.jproteome.0c00383","volume":"19","author":"I Maffucci","year":"2020","unstructured":"Maffucci I, Contini A (2020) In silico drug repurposing for SARS-CoV-2 main proteinase and spike proteins. J Proteome Res 19(11):4637\u20134648. https:\/\/doi.org\/10.1021\/acs.jproteome.0c00383","journal-title":"J Proteome Res"},{"key":"16427_CR20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2174\/1871530320666200427112902","volume":"20","author":"T Magrone","year":"2020","unstructured":"Magrone T, Magrone M, Jirillo E (2020) Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target - a pserspective. Endocr Metab Immune Disord Drug Targets 20:807\u2013811. https:\/\/doi.org\/10.2174\/1871530320666200427112902","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"16427_CR21","doi-asserted-by":"publisher","first-page":"m2378","DOI":"10.1136\/bmj.m2378","volume":"369","author":"E Mahase","year":"2020","unstructured":"Mahase E (2020) Hydroxychloroquine for covid-19: the end of the line? BMJ (Clin Res Ed) 369:m2378. https:\/\/doi.org\/10.1136\/bmj.m2378","journal-title":"BMJ (Clin Res Ed)"},{"key":"16427_CR22","doi-asserted-by":"publisher","first-page":"e00864","DOI":"10.1016\/j.idcr.2020.e00864","volume":"21","author":"AE Malek","year":"2020","unstructured":"Malek AE, Granwehr BP, Kontoyiannis DP (2020) Doxycycline as a potential partner of COVID-19 therapies. IDCases 21:e00864. https:\/\/doi.org\/10.1016\/j.idcr.2020.e00864","journal-title":"IDCases"},{"issue":"2","key":"16427_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5582\/ddt.2020.01017","volume":"14","author":"GH Marin","year":"2020","unstructured":"Marin GH (2020) Facts and reflections on COVID-19 and anti-hypertensives drugs. Drug Discov Ther 14(2):105\u2013106. https:\/\/doi.org\/10.5582\/ddt.2020.01017","journal-title":"Drug Discov Ther"},{"issue":"5","key":"16427_CR24","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1096\/fj.202000919","volume":"34","author":"EA Meyerowitz","year":"2020","unstructured":"Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, Kim AY, Reeves PM, Poznansky MC (2020) Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 34(5):6027\u20136037","journal-title":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology"},{"issue":"10232","key":"16427_CR25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(20)30894-1","volume":"395","author":"A Mullard","year":"2020","unstructured":"Mullard A (2020) Flooded by the torrent: the COVID-19 drug pipeline. Lancet (London, England) 395(10232):1245\u20131246. https:\/\/doi.org\/10.1016\/S0140-6736(20)30894-1","journal-title":"Lancet (London, England)"},{"issue":"3","key":"16427_CR26","doi-asserted-by":"publisher","first-page":"e219","DOI":"10.1016\/j.ddtec.2012.07.009","volume":"9","author":"MS Murgueitio","year":"2012","unstructured":"Murgueitio MS, Bermudez M, Mortier J, Wolber G (2012) In silico virtual screening approaches for anti-viral drug discovery. Drug discovery today. Technologies 9(3):e219\u2013e225. https:\/\/doi.org\/10.1016\/j.ddtec.2012.07.009","journal-title":"Technologies"},{"key":"16427_CR27","doi-asserted-by":"publisher","unstructured":"Paccoud O, Tubach F, Baptiste A, Bleibtreu A, Hajage D, Monsel G, Tebano G, Boutolleau D, Klement E, Godefroy N, Palich R, Itani O, Fayssal A, Valantin M-A, Tubiana R, Burrel S, Calvez V, Caumes E, Marcelin A-G, Pourcher V (2020) Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital. Clin Infect Dis 18:ciaa791.\u00a0https:\/\/doi.org\/10.1093\/cid\/ciaa791","DOI":"10.1093\/cid\/ciaa791"},{"key":"16427_CR28","doi-asserted-by":"publisher","first-page":"106053","DOI":"10.1016\/j.ijantimicag.2020.106053","volume":"56","author":"A Pani","year":"2020","unstructured":"Pani A, Lauriola M, Romandini A, Scaglione F (2020) Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents 56:106053. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106053","journal-title":"Int J Antimicrob Agents"},{"key":"16427_CR29","doi-asserted-by":"publisher","unstructured":"Pathak Y, Mishra A, Tripathi V (2020) Rifampicin may be repurposed for COVID-19 treatment: insights from an in-silico study.\u00a0PREPRINT (Version 1) available at Research Square. https:\/\/doi.org\/10.21203\/rs.3.rs-22546\/v1","DOI":"10.21203\/rs.3.rs-22546\/v1"},{"key":"16427_CR30","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/j.xphs.2021.03.004","volume":"110","author":"KA Peele","year":"2021","unstructured":"Peele KA, Kumar V, Parate S, Srirama K, Lee KW, Venkateswarulu TC (2021) In silico drug repurposing using FDA approved drugs against membrane protein of SARS-CoV-2. J Pharm Sci 110:2346\u20132354. https:\/\/doi.org\/10.1016\/j.xphs.2021.03.004","journal-title":"J Pharm Sci"},{"issue":"4","key":"16427_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1747-0285.2007.00475.x","volume":"69","author":"D Plewczynski","year":"2007","unstructured":"Plewczynski D, Hoffmann M, von Grotthuss M, Ginalski K, Rychewski L (2007) In silico prediction of SARS protease inhibitors by virtual high throughput screening. Chem Biol Drug Des 69(4):269\u2013279. https:\/\/doi.org\/10.1111\/j.1747-0285.2007.00475.x","journal-title":"Chem Biol Drug Des"},{"key":"16427_CR32","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, P\u00e9rez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"16427_CR33","doi-asserted-by":"publisher","first-page":"117765","DOI":"10.1016\/j.lfs.2020.117765","volume":"254","author":"V Pooladanda","year":"2020","unstructured":"Pooladanda V, Thatikonda S, Godugu C (2020) The current understanding and potential therapeutic options to combat COVID-19. Life Sci 254:117765. https:\/\/doi.org\/10.1016\/j.lfs.2020.117765","journal-title":"Life Sci"},{"issue":"2","key":"16427_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12539-015-0109-8","volume":"8","author":"U Raj","year":"2016","unstructured":"Raj U, Varadwaj PK (2016) Flavonoids as multi-target inhibitors for proteins associated with Ebola virus: in silico discovery using virtual screening and molecular docking studies. Interdiscip Sci Comput Life Sci 8(2):132\u2013141. https:\/\/doi.org\/10.1007\/s12539-015-0109-8","journal-title":"Interdiscip Sci Comput Life Sci"},{"key":"16427_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32466-1","volume-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","author":"MN Ramasamy","year":"2020","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA et al (2020) Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet, London, England. https:\/\/doi.org\/10.1016\/S0140-6736(20)32466-1"},{"key":"16427_CR36","doi-asserted-by":"publisher","unstructured":"Ren L, Xu W, Overton JL, Yu S, Chiamvimonvat N, Thai PN (2020) Assessment of hydroxychloroquine and chloroquine safety profiles: a systematic review and meta-analysis. medRxiv : the preprint server for health sciences. doi: https:\/\/doi.org\/10.1101\/2020.05.02.20088872","DOI":"10.1101\/2020.05.02.20088872"},{"issue":"651","key":"16427_CR37","doi-asserted-by":"publisher","first-page":"eabe1202","DOI":"10.1126\/scisignal.abe1202","volume":"13","author":"M Rosas-Lemus","year":"2020","unstructured":"Rosas-Lemus M, Minasov G, Shuvalova L, Inniss NL, Kiryukhina O, Brunzelle J, Satchell KJF (2020) High-resolution structures of the SARS-CoV-2 2\u2032- O -methyltransferase reveal strategies for structure-based inhibitor design. Sci Signal 13(651):eabe1202. https:\/\/doi.org\/10.1126\/scisignal.abe1202","journal-title":"Sci Signal"},{"key":"16427_CR38","doi-asserted-by":"publisher","unstructured":"Sen Gupta PS, Biswal S, Singha D, Rana MK (2020) Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2. J Biomol Struct Dyn\u00a039(14):5327\u20135333.\u00a0https:\/\/doi.org\/10.1080\/07391102.2020.1784795","DOI":"10.1080\/07391102.2020.1784795"},{"key":"16427_CR39","doi-asserted-by":"publisher","unstructured":"Sette-DE-Souza PH, Costa MJF, Amaral-Machado L, Ara\u00fajo\u00a0FADC, Almeida Filho AT, Lima LRA (2021) Dental workers in front-line of COVID-19: an in silico evaluation targeting their prevention. J Appl Oral Sci 26;29:e20200678.\u00a0https:\/\/doi.org\/10.1590\/1678-7757-2020-0678","DOI":"10.1590\/1678-7757-2020-0678"},{"issue":"1","key":"16427_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12985-021-01515-1","volume":"18","author":"C Shang","year":"2021","unstructured":"Shang C, Zhuang X, Zhang H, Li Y, Zhu Y, Lu J, Ge C, Cong J, Li T, Tian M, Jin N, Li X (2021) Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virol J 18(1):46. https:\/\/doi.org\/10.1186\/s12985-021-01515-1","journal-title":"Virol J"},{"key":"16427_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/imm.13222","volume":"160","author":"HR Sharpe","year":"2020","unstructured":"Sharpe HR, Gilbride C, Allen E, Belij-Rammerstorfer S, Bissett C, Ewer K, Lambe T (2020) The early landscape of COVID-19 vaccine development in the UK and rest of the world. Immunology 160:223\u2013232. https:\/\/doi.org\/10.1111\/imm.13222","journal-title":"Immunology"},{"key":"16427_CR42","doi-asserted-by":"publisher","unstructured":"Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, Mlisana K, Gottberg A von, Walaza S, Allam M, Ismail A, Mohale T, Glass AJ, Engelbrecht S, van Zyl G, Preiser W, Petruccione F, Sigal A, Hardie D, Marais G, Hsiao M, Korsman S, Davies M-A, Tyers L, Mudau I, York D, Maslo C, Goedhals D, Abrahams S, Laguda-Akingba O, Alisoltani-Dehkordi A, Godzik A, Wibmer CK, Sewell BT, Louren\u00e7o J, Alcantara LCJ, Pond SLK, Weaver S, Martin D, Lessells RJ, Bhiman JN, Williamson C, Oliveira T de (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. https:\/\/doi.org\/10.1101\/2020.12.21.20248640","DOI":"10.1101\/2020.12.21.20248640"},{"issue":"5","key":"16427_CR43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"T Thanh Le","year":"2020","unstructured":"Thanh Le T, Andreadakis Z, Kumar A, G\u00f3mez Rom\u00e1n R, Tollefsen S, Saville M, Mayhew S (2020) The COVID-19 vaccine development landscape. Nat Rev Drug Discov 19(5):305\u2013306. https:\/\/doi.org\/10.1038\/d41573-020-00073-5","journal-title":"Nat Rev Drug Discov"},{"key":"16427_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1","volume-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","author":"M Voysey","year":"2020","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA et al (2020) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, London, England. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1"},{"issue":"4","key":"16427_CR45","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen K-Y, Wang Q, Zhou H, Yan J, Qi J (2020) Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181(4):894\u2013904.e9. https:\/\/doi.org\/10.1016\/j.cell.2020.03.045","journal-title":"Cell"},{"key":"16427_CR46","doi-asserted-by":"publisher","unstructured":"Wise J (2020) Covid-19: new coronavirus variant is identified in UK. BMJ (Clinical research ed.)\u00a0371:m4857.\u00a0https:\/\/doi.org\/10.1136\/bmj.m4857","DOI":"10.1136\/bmj.m4857"},{"key":"16427_CR47","unstructured":"World Health Organization (2020) Novel coronavirus \u2013 China. https:\/\/www.who.int\/csr\/don\/12-january-2020-novel-coronavirus-china\/en\/. Accessed 11 Jun 2020"},{"issue":"6483","key":"16427_CR48","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (New York, NY) 367(6483):1260\u20131263. https:\/\/doi.org\/10.1126\/science.abb2507","journal-title":"Science (New York, NY)"},{"key":"16427_CR49","doi-asserted-by":"publisher","unstructured":"Wu C, Ye D, Mullick AE, Li Z, Danser AHJ, Daugherty A, Lu HS (2020) Effects of renin-angiotensin inhibition on ACE2 and TMPRSS2 expression: insights into COVID-19. bioRxiv : the preprint server for biology. doi: https:\/\/doi.org\/10.1101\/2020.06.08.137331","DOI":"10.1101\/2020.06.08.137331"},{"issue":"12","key":"16427_CR50","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1021\/cb800176t","volume":"3","author":"Z Zhou","year":"2008","unstructured":"Zhou Z, Khaliq M, Suk J-E, Patkar C, Li L, Kuhn RJ, Post CB (2008) Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem Biol 3(12):765\u2013775. https:\/\/doi.org\/10.1021\/cb800176t","journal-title":"ACS Chem Biol"},{"issue":"7798","key":"16427_CR51","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, Chen H-D, Chen J, Luo Y, Guo H, Jiang R-D, Liu M-Q, Chen Y, Shen X-R, Wang X et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270\u2013273. https:\/\/doi.org\/10.1038\/s41586-020-2012-7","journal-title":"Nature"},{"issue":"8","key":"16427_CR52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727\u2013733. https:\/\/doi.org\/10.1056\/NEJMoa2001017","journal-title":"N Engl J Med"}],"container-title":["Environmental Science and Pollution Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-021-16427-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11356-021-16427-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-021-16427-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T05:41:52Z","timestamp":1643262112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11356-021-16427-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["16427"],"URL":"https:\/\/doi.org\/10.1007\/s11356-021-16427-4","relation":{},"ISSN":["0944-1344","1614-7499"],"issn-type":[{"value":"0944-1344","type":"print"},{"value":"1614-7499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}